4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine
Status:
Withdrawn
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This phase 2 randomized study will be used to test the efficacy of 4-aminopyridine (4AP) or
atenolol to reduce severity and frequency of vestibular and headache symptoms of vestibular
migriane sufferers. Blinded study drug will be taken by mouth twice a day for 14 weeks on
study.